TG Therapeutics Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
82.82 M |
Public Float |
65.97 M |
TG Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$2.1 |
Market Cap |
$778.46 M |
Shares Outstanding |
90.84 M |
Public Float |
72.5 M |
Address |
2 Gansevoort Street New York New York 10014 United States |
Employees | - |
Website | http://www.tgtherapeutics.com |
Updated | 07/08/2019 |
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. It also involves developing TG-1101 and TGR-1202 therapies targeting hematological malignancies. The company was founded by Michael Sean Weiss and Laurence H. |